Objectives: West Nile virus (WNV) infection causes severe meningitis and encephalitis in a subset of patients. WNV-induced apoptosis has been suggested to contribute to WNV pathogenesis. Tetracyclines exert antiviral effects against HIV and inhibit apoptosis in different models of neuronal disease. Here, the effects of the tetracyclines minocycline, demeclocycline and chlortetracycline were observed on WNV replication and WNV-induced apoptosis in different human CNS-derived cell types ( primary human brain neurons, primary human retinal pigment epithelial cells and T98G human glioma cell line).
Introduction
West Nile virus (WNV) is a neurotropic RNA virus of the Flaviviridae family that is mainly transmitted by Culex mosquitoes and causes West Nile encephalitis in humans, animals and birds.
1,2 WNV infections typically result in subclinical or nonspecific, mild febrile illnesses. However, WNV infection may also result in severe meningitis and encephalitis. Three thousand one hundred and thirty-five cases of human WNV disease were reported to CDC from 41 states of the USA and from the District of Columbia from 6 January to 10 October in 2006. 3 There is no vaccine against WNV infection licensed for humans, and therapy of WNV encephalitis is limited to supportive care as no effective antiviral option has been established. Different clinically approved antiviral agents, including ribavirin and a-interferon, showed some degree of inhibition of WNV replication in vitro; however, none of them was proved to be beneficial in vivo. 4 WNV-induced cell death includes caspase-dependent apoptosis in neuronal cells in vitro and in vivo, suggesting caspase/apoptosis inhibition as a possible novel therapeutic strategy to restrict WNV-induced CNS injury. 5, 6 Tetracyclines have been used for decades for the treatment of various Gram-positive and Gram-negative infections. 7 Minocycline was shown to possess anti-apoptotic (neuroprotective) as well as antiviral and antiinflammatory properties against HIV-induced encephalitis. 8 In the present study, we observed effects of the tetracyclines minocycline, demeclocycline and chlortetracycline on replication of two different WNV strains (NY385-99 and Ug37) in different human CNS-derived cell cultures including primary cultures of neurons.
Materials and methods

Cell culture
Human brain neurons (HBNs) and neuronal medium were obtained from Sciencell, CA, USA and grown in accordance with the manufacturer's protocol. Cells were seeded at a density of 4 Â 10 5 cells per well in a 96-multiwell plate with a complete medium change every 24 h. After $3 days, when cells had formed a complex neuritic network, cultures were used for the experiments.
Human retinal pigment epithelial (HRPE) cells were isolated and cultured as described previously.
9
T98G cells, derived from a patient with stage IV glioma, were obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were grown at 378C in Iscove's modified Dulbecco's medium supplemented with 10% heat-inactivated fetal calf serum, containing 100 IU/mL penicillin and 100 mg/mL streptomycin.
Virus preparation
WNV strain NY385-99 was kindly provided by Dr Jan ter Meulen (Institut für Virologie, Phillips-Universität, Marburg, Germany). 10 WNV strain Ug37 was kindly provided by Dr Christian Drosten (Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany). Viruses were propagated on Vero cells and stocks were stored at 2808C. Virus titres were determined as 50% tissue culture infectious dose (TCID 50 )/mL on Vero cell monolayers in 96-well microtitre plates. For viral infection, cells were incubated with virus at a multiplicity of infection (MOI) of 0.1 for 60 min followed by washing four times with PBS.
Drugs
Minocycline, demeclocycline and chlortetracycline were from Sigma-Aldrich (Taufkirchen, Germany). The c-Jun N-terminal kinase (JNK) inhibitor L-JNKi was obtained from Calbiochem (Heidelberg, Germany). It was used at non-toxic concentrations.
Cytopathic effect (CPE) reduction assay
Confluent T98G monolayers grown in 96-well microtitre plates were pre-treated with the respective tetracycline derivative for 24 h prior to infection with WNV at an MOI of 0.1. Following a 1 h virus incubation period, the medium was removed and infected cells were incubated in medium containing different concentrations of drugs at the respective concentration. The virus-induced CPE was recorded at 48 h post-infection using an inverted light microscope.
Virus yield reduction assay
Cells were pre-treated with different concentrations of minocycline for 24 h prior to infection with WNV at an MOI of 0.1. Following a 1 h virus incubation period, the medium was removed and infected cultures were incubated with medium containing respective concentrations of minocycline. At 48 h post-infection cultures were deepfrozen at 2808C. After thawing of the cultures, infectious virus titres were determined as TCID 50 /mL on Vero cell monolayers in 96-well microtitre plates.
Western blots
Western blots were performed using the enhanced chemiluminescence method, as described previously. 11 The following primary antibodies were used: anti-JNK, anti-phospho-JNK, anti-c-jun and anti-phospho-c-jun (all obtained from Cell Signalling, Frankfurt, Germany).
Viability assay
The cellular viability was assessed on confluent cell layers with the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay method, as described previously. 11 The viability was expressed as percentage of non-treated control.
Immunostaining
Virus envelope-antigen, activated caspase 3 and the 85 kDa fragment of cleaved poly(ADP-ribose) polymerase (PARP) were detected by immunostaining. For this purpose, cells were fixed with 60:40 methanol/acetone for 15 min. The following primary antibodies were used: WNV-E1 (Chemicon, Hofheim Germany), caspase 3 (active) (R&D Systems, Wiesbaden, Germany) and PARP p85-fragment (Promega, Mannheim, Germany). Biotin-conjugated secondary monoclonal antibodies were used and visualization was performed with streptavidin-peroxidase complex with 3-amino-9-ethylcarbazole as a substrate.
Statistics
Results are expressed as mean values+SD of at least three experiments. Comparisons between two groups were performed using Student's t-test; three or more groups were compared by analysis of variance followed by the Student -Newman-Keuls test. P values less than 0.05 were considered to be significant.
Results
Effect of different tetracycline derivatives on WNV-induced CPE in T98G cells
T98G cells are highly susceptible to WNV-induced CPE, as characterized by cell rounding and detachment ( Figure 1 ). In contrast, WNV infection of HBN (data not shown) or HRPE 11 does not result in CPE formation. This makes T98G cells useful for rapid screening of antiviral substances. Therefore, the influence of minocycline, demeclocycline or chlortetracycline on WNV-induced CPE was investigated at different concentrations ranging from 0 to 40 mg/mL in T98G human glioma cells. Minocycline and demeclocycline exerted anti-WNV activity with minocycline showing the highest selectivity index (SI) for both WNV strains (NY385-99 and Ug37; Table 1 ). All further experiments used minocycline. Treatment of T98G cells with 40 mg/mL minocycline resulted in a low but significant decrease in cell viability. Lower concentrations did not affect T98G cell viability. In contrast, minocycline did not influence cellular viability of HBN or HRPE cells at concentrations up to 40 mg/mL (data not shown).
Minocycline inhibits WNV replication in different human brain-derived cell types
Minocycline inhibits WNV-induced apoptosis
WNV infection was shown to induce apoptosis as indicated by the detection of activated caspase 3 and PARP cleavage. 
Minocycline inhibits WNV-induced JNK phosphorylation
JNK signalling was shown to have a pro-apoptotic role in neurons. 12, 13 Moreover, minocycline inhibited JNK signalling in microglial cells.
14 Therefore, we investigated the influence of minocycline on JNK signalling in our system. T98G cells were treated with minocycline (10-40 mg/mL). 
JNK inhibitor L-JNKi inhibits WNV replication and WNV-induced apoptosis
To investigate whether JNK inhibition is suitable to inhibit WNV replication and WNV-induced apoptosis, the JNK inhibitor L-JNKi was used. L-JNKi (2 mg/mL) was shown to inhibit JNK phosphorylation, c-jun expression and c-jun phosphorylation in WNV strain NY385-99-infected T98G cells (Figure 4a 
Discussion
In the present study, minocycline is demonstrated to inhibit WNV replication in both transformed and primary human CNS-derived cells, including human neurons. Minocycline was earlier shown to exert neuroprotective, antiviral and antiinflammatory properties in different models of virus-induced encephalitis. In a murine model of reovirus encephalitis, minocycline delayed disease onset and progression. Virus-induced CNS injury, apoptosis, virus titre and antigen expression were significantly decreased in the brains of minocycline-treated mice. 15 In an in vivo simian immunodeficiency virus model of HIV CNS disease, minocycline reduced the severity of encephalitis, suppressed viral load in the brain and decreased the expression of CNS inflammatory markers. 8 Minocycline inhibited WNV replication at concentrations between 5 and 40 mg/mL. These concentrations are achievable in human tissue. Levels of minocycline in the sera of patients treated with a standard dosage of 100 mg/day reached up to 10 mg/mL. 16 In two double-blind, randomized, placebocontrolled feasibility trials of minocycline in patients with amyotrophic lateral sclerosis, the mean tolerated dose was 387 mg/day (5.5 mg/kg per day for a 79 kg individual). 17 Furthermore, it should be noted that minocycline has a high degree of lipid solubility that results in concentrations in tissue that exceed those in serum. 18 WNV-induced caspase-dependent apoptosis was suggested to contribute directly to the pathogenesis of WNV encephalitis. 5, 6 In addition to inhibition of WNV replication, minocycline also inhibited WNV-induced apoptosis, as indicated by inhibition of caspase 3 activation and PARP cleavage. Previous studies demonstrated that WNV induces apoptosis in infected neuronal cells, but not in non-infected cells. 5 Moreover, repression of WNV-induced apoptosis was shown previously to protect WNV-infected cells without affecting virus replication or spread. 5, 6 Sindbis virus is an RNA virus belonging to the alphaviruses, which is related to the Flaviviruses and also causes epidemic, mosquito-borne encephalitis in humans. Previous studies revealed that minocycline does not interfere with replication of Sindbis virus, indicating that the antiviral activity of minocycline may vary even between related RNA viruses. Despite lack of antiviral effects, minocycline protected mice from fatal Sindbis virus encephalitis by neuroprotective effects. 19, 20 Thus, both mechanisms-inhibition of WNV replication and neuroprotective effects (that do not depend on antiviral activity)-are likely to contribute to inhibition of WNV-induced apoptosis by minocycline. Therefore, individuals suffering from severe WNV disease of the CNS may benefit from minocycline by antiviral effects and by neuroprotective effects that are independent of antiviral activity.
Minocycline inhibited JNK signalling in microglial cells.
14 Moreover, there is strong evidence that JNK signalling has a pro-apoptotic role in neurons. 12, 13 Our data show that minocycline suppresses JNK signalling, probably by activity upstream of JNK in T98G cells. The JNK inhibitor L-JNKi exerted effects similar to minocycline. It inhibited WNV-induced CPE formation and decreased WNV infectious titres. In addition, L-JNKi inhibited WNV-induced apoptosis. Therefore, minocycline-induced anti-WNV effects are likely to be due to JNK inhibition. These findings are in concordance with previous results, in which the JNK inhibitor SP600125 was found to reduce infectious WNV titres in the mosquito-derived cell line C6/36. 21 In conclusion, minocycline inhibits WNV replication and WNV-induced apoptosis, probably by inhibition of JNK signalling. It represents a clinically approved drug that shows high penetration across the blood -brain barrier. Because it is a safe, frequently used, inexpensive drug, minocycline could be readily considered for testing in patients suffering from WNV encephalitis.
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